SG10201609511XA - Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof - Google Patents

Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof

Info

Publication number
SG10201609511XA
SG10201609511XA SG10201609511XA SG10201609511XA SG10201609511XA SG 10201609511X A SG10201609511X A SG 10201609511XA SG 10201609511X A SG10201609511X A SG 10201609511XA SG 10201609511X A SG10201609511X A SG 10201609511XA SG 10201609511X A SG10201609511X A SG 10201609511XA
Authority
SG
Singapore
Prior art keywords
subfamily
simian adenoviruses
adenoviruses
simian
Prior art date
Application number
SG10201609511XA
Inventor
Soumitra Roy
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG10201609511XA publication Critical patent/SG10201609511XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
SG10201609511XA 2012-05-18 2013-05-17 Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof SG10201609511XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649007P 2012-05-18 2012-05-18
US201361784142P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201609511XA true SG10201609511XA (en) 2016-12-29

Family

ID=49584464

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407343XA SG11201407343XA (en) 2012-05-18 2013-05-17 Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG10201609511XA SG10201609511XA (en) 2012-05-18 2013-05-17 Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407343XA SG11201407343XA (en) 2012-05-18 2013-05-17 Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof

Country Status (11)

Country Link
US (2) US9217159B2 (en)
EP (1) EP2850194A4 (en)
JP (1) JP6293738B2 (en)
KR (1) KR20150014505A (en)
CN (1) CN105473723A (en)
AU (1) AU2013262626B2 (en)
BR (1) BR112014028684A2 (en)
CA (1) CA2873509A1 (en)
MX (1) MX358019B (en)
SG (2) SG11201407343XA (en)
WO (1) WO2013173702A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
KR102089121B1 (en) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Oncolytic adenovirus compositions
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
MX2017004507A (en) 2014-10-06 2017-06-28 Univ Pennsylvania Compositions and methods for isolation of circulating tumor cells (ctc).
JP6401871B2 (en) 2014-11-05 2018-10-10 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． AADC polynucleotide for the treatment of Parkinson's disease
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
KR20220163505A (en) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3458588A4 (en) 2016-05-18 2020-01-15 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
EP3490610A4 (en) * 2016-08-01 2020-05-20 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
EP3831281A1 (en) 2016-08-30 2021-06-09 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JP2020518258A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Amyotrophic lateral sclerosis (ALS) treatment composition and method
TW202333779A (en) 2017-05-08 2023-09-01 美商磨石生物公司 Alphavirus neoantigen vectors
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
MA50502A (en) * 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv ADENOVIRUS AND RELATED USES
US11459583B2 (en) 2017-10-31 2022-10-04 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
CN111295391B (en) 2017-10-31 2023-12-05 扬森疫苗与预防公司 Adenovirus and use thereof
JP7438943B2 (en) * 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Adenovirus and its uses
US20220153871A1 (en) 2018-01-04 2022-05-19 Iconic Therapeutics, Inc. Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
EP3807404A1 (en) 2018-06-13 2021-04-21 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
EP3826719A1 (en) 2018-07-24 2021-06-02 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
TW202035689A (en) 2018-10-04 2020-10-01 美商航海家醫療公司 Methods for measuring the titer and potency of viral vector particles
SG11202103425YA (en) 2018-10-05 2021-05-28 Voyager Therapeutics Inc Engineered nucleic acid constructs encoding aav production proteins
WO2020081490A1 (en) 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
CN110437317B (en) * 2019-01-30 2023-05-02 上海科技大学 Adeno-associated virus with variant capsid proteins and uses thereof
EP3917566A4 (en) 2019-01-31 2022-10-26 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
BR122024002387A2 (en) 2019-05-30 2024-03-12 Gritstone Bio, Inc. ADENOVIRUS VECTORS, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEOTIDE SEQUENCE, ISOLATED CELL, VECTOR, KIT, USES OF A VECTOR, METHOD FOR MAKING THE VECTOR, METHODS FOR PRODUCING A VIRUS AND VIRAL VECTOR
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
BR112023015303A2 (en) 2021-02-01 2023-11-14 Regenxbio Inc METHOD TO TREAT CLN2 DISEASE DUE TO TPP1 DEFICIENCY IN A SUBJECT

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1364343A1 (en) 1984-07-13 1988-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Method of producing manъs leukocytic interferon alfa-2
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4732683A (en) 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
CA2200869A1 (en) 1994-10-19 1996-05-02 Bruce C. Trapnell Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU1822499A (en) 1997-12-12 1999-06-28 Saint Louis University Ctip, a novel protein that interacts with ctbp and uses therefor
EP1044274A2 (en) * 1998-01-16 2000-10-18 Genzyme Corporation Adenoviral vectors with modified capsid proteins
JP2002506652A (en) 1998-03-20 2002-03-05 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for helper-free production of recombinant adeno-associated virus
WO2000011140A1 (en) 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
CA2341061A1 (en) 1998-08-27 2000-03-09 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6955808B2 (en) 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
KR100808348B1 (en) 2000-01-31 2008-02-27 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccine for the prophylactic or therapeutic immunization against hiv
US6740525B2 (en) 2000-02-09 2004-05-25 Genvec, Inc. Adenoviral capsid containing chimeric protein IX
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CA2450470C (en) 2001-06-22 2012-08-28 The Trustees Of The University Of Pennsylvania Method for rapid screening of bacterial transformants and novel simian adenovirus proteins
CA2466431C (en) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US7491508B2 (en) 2003-06-20 2009-02-17 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
FR2860004A1 (en) 2003-09-18 2005-03-25 Roussy Inst Gustave Adenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus
LT2163260T (en) 2004-01-23 2017-06-26 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
EP1718315A4 (en) 2004-02-06 2008-08-13 Univ Monash High dose, short interval use of sulfated polysaccharides for the treatment of infections
AU2005293568B2 (en) 2004-10-13 2010-10-28 Beth Israel Deaconess Medical Center Inc. Improved adenoviral vectors and uses thereof
KR20070104881A (en) 2004-10-14 2007-10-29 크루셀 홀란드 비.브이. Malaria prime/boost vaccines
AU2006212012B2 (en) 2005-02-12 2011-10-13 Swedish Orphan Biovitrum International Ab Methods and uses of antibodies in the purification of interferon
EP1880012B1 (en) 2005-05-12 2015-07-08 Glaxo Group Limited Vaccine composition
EP1893636A2 (en) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
DE602007004470D1 (en) 2006-04-28 2010-03-11 Univ Pennsylvania MODIFIED ADENOVIRUS HEXON PROTEIN AND APPLICATIONS THEREOF
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
KR101761683B1 (en) 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Simian subfamily b adenoviruses sadv-28,27,-29,-32,-33, and -35 and uses thereof
PL2220241T3 (en) 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenovirus comprising a Simian E Adenovirus SAdV-39 capsid hexon protein and uses thereof
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
JP5809978B2 (en) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Simian adenovirus SAdV-43, -45, -46, -47, -48, -49 and -50 and their uses
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
SG172935A1 (en) * 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
WO2013055268A1 (en) 2011-10-13 2013-04-18 Telefonaktiebolaget L M Ericsson (Publ) Method and node related to channel estimation

Also Published As

Publication number Publication date
CA2873509A1 (en) 2013-11-21
KR20150014505A (en) 2015-02-06
US20160083749A1 (en) 2016-03-24
US10113182B2 (en) 2018-10-30
AU2013262626B2 (en) 2018-11-29
WO2013173702A3 (en) 2014-03-13
SG11201407343XA (en) 2014-12-30
CN105473723A (en) 2016-04-06
US20130315871A1 (en) 2013-11-28
MX358019B (en) 2018-08-02
EP2850194A2 (en) 2015-03-25
BR112014028684A2 (en) 2017-07-25
AU2013262626A1 (en) 2014-12-04
WO2013173702A2 (en) 2013-11-21
WO2013173702A9 (en) 2015-05-28
US9217159B2 (en) 2015-12-22
MX2014014024A (en) 2015-02-10
JP2015519058A (en) 2015-07-09
EP2850194A4 (en) 2016-06-08
JP6293738B2 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
SG10201609511XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
HK1215589A1 (en) Recombinant adenoviruses and use thereof
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL238959A (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL235155B (en) Arginase inhibitor compounds, compositions comprising same and uses thereof
PL2831055T3 (en) Polymerizable alkylidene-1,3-dioxolan-2-ones and use thereof
PL2903754T3 (en) Bucket and its use
HK1205166A1 (en) Polymer, composition and use
IL233824A (en) 1h-indazole-3-carboxamide compounds, compositions comprising them and uses thereof
HK1211580A1 (en) Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
EP2837627A4 (en) Amidopyridine derivative, and use thereof
EP2889307A4 (en) Alpha-conotoxin peptide, and medical composition and purpose thereof
IL226961B (en) Anti-regurgitation and/or anti-gastro-oesophageal reflux composition, preparation and uses
IL280316B (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237542B (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237540B (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237538B (en) Bolaamphiphilic compounds, compositions and uses thereof
EP2807545A4 (en) Desktop extension
IL237539A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
AU2012904440A0 (en) Barrow
AU2012904451A0 (en) Improved Diverter Flow
AU2012902726A0 (en) Spreadsheet improvements
AU2012902593A0 (en) Improved Recombinant Viruses
AU2012901107A0 (en) Chlorination
AU2012905068A0 (en) Authenticable Security Element